Amylin Pharmaceuticals | search
Click here to view Amylin Pharmaceuticals news from 60+ newspapers.
Bookmark or Share- Amylin Pharmaceuticals, Inc. -- Company HistoryAmylin Pharmaceuticals, Inc. develops medicines to treat diabetes, obesity, and cardiovascular disease. The company's two lead drugs are SYMLIN and exenatide, both developed to treat diabetes. SYMLIN and exenatide are in late-stage development, nearing full approval for commercialization.
- AstraZeneca and Bristol-Myers Squibb complete expansion of diabetes ...Amylin is committed to delivering novel therapies that transform the way diabetes and other metabolic disorders are treated. The acquisition of Amylin by Bristol-Myers Squibb was completed 9 August 2012.
- Amylin Pharmaceuticals - Crunchbase Company Profile & FundingAmylin Pharmaceuticals is a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs. Develops a line of diagnostic and therapeutic products for diabetics. Working towards a cure for diabetes by challenging science, changing lives.
- Amylin Pharmaceuticals - WikipediaAmylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases.
- Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co ...Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.
More
